Opinion
Video
Author(s):
Comprehensive insights on treatment considerations and managing immunotherapy-related adverse effects for patients with bladder cancer.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk
Dr. Schwen on focal therapies for prostate cancer
Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic
Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care
Durvalumab plus BCG significantly improves DFS in NMIBC
Physical function and frailty measures offer distinct insights in patients with bladder cancer
PEACE-3 data for radium-223/enzalutamide published in Annals of Oncology
Phase 2 trial launches of combination immunotherapy for mCRPC
Study findings highlight gender gaps in oncology authorship and citation
ORIC-944 shows promise in combination with AR inhibitors in mCRPC